These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
642 related articles for article (PubMed ID: 35870763)
1. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis. Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis. Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016 [No Abstract] [Full Text] [Related]
3. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis. Zhu Y; Liu C; Xu Z; Zou Z; Xie T; Xing P; Wang L; Li J Chin Med J (Engl); 2023 Nov; 136(21):2551-2561. PubMed ID: 37160733 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L Front Immunol; 2021; 12():731546. PubMed ID: 34484242 [TBL] [Abstract][Full Text] [Related]
5. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction. Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis. Xu Z; Liu C; Zhu Y; Zou Z; Xie T; Xing P; Wang L; Li J BMC Cancer; 2022 May; 22(1):514. PubMed ID: 35525919 [TBL] [Abstract][Full Text] [Related]
8. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs. Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541 [TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364 [TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Yang Y; Chen W; Dong L; Duan L; Gao P Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158 [TBL] [Abstract][Full Text] [Related]
12. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349 [TBL] [Abstract][Full Text] [Related]
13. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS). Lu S; Dong X; Jian H; Chen J; Chen G; Sun Y; Ji Y; Wang Z; Shi J; Lu J; Chen S; Lv D; Zhang G; Liu C; Li J; Yu X; Lin Z; Yu Z; Wang Z; Cui J; Xu X; Fang J; Feng J; Xu Z; Ma R; Hu J; Yang N; Zhou X; Wu X; Hu C; Zhang Z; Lu Y; Hu Y; Jiang L; Wang Q; Guo R; Zhou J; Li B; Hu C; Tong W; Zhang H; Ma L; Chen Y; Jie Z; Yao Y; Zhang L; Weng J; Li W; Xiong J; Ye X; Duan J; Yang H; Sun M; Wei H; Wei J; Zhang Z; Wu Q Cancer Commun (Lond); 2024 Sep; 44(9):1005-1017. PubMed ID: 39016053 [TBL] [Abstract][Full Text] [Related]
14. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis. Yu Z; Xu F; Zou J Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. Dai L; Luo CY; Hu GX; Chen G; Wu CX; Yin J; Jiang ZY; Hu GF; Zhao J; Fu WF Ann Palliat Med; 2020 Jul; 9(4):2062-2071. PubMed ID: 32692221 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis. Peng Y; Zhao Q; Liao Z; Ma Y; Ma D Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. Yi L; Fan J; Qian R; Luo P; Zhang J Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. Zeng X; Wan X; Xu J; Wang H; Chen H; Zeng Q; Zhang W; Zhao B Aging (Albany NY); 2020 Apr; 12(8):7129-7162. PubMed ID: 32324592 [TBL] [Abstract][Full Text] [Related]
19. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]